Bernadette Connaughton Halozyme Therapeutics, Inc. (HALO) insider trading activity

Bernadette Connaughton is Director of HALOZYME THERAPEUTICS, INC.. Currently has a direct ownership of 40,123 shares of HALO, which is worth approximately $2.81 Million. The most recent transaction as insider was on Jan 05, 2026, when has been sold 2,000 shares (Common Stock) at a price of $70.25 per share, resulting in proceeds of $140,500. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 40.1K

10.74% 3M change

14.24% 12M change

Total Value Held $2.81 Million

Bernadette Connaughton Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 05 2026	SELL Open market or private sale	$140,500 $70.25 p/Share	2,000 Reduced 4.75%	40,123 Common Stock
Dec 01 2025	SELL Open market or private sale	$59,356 $71.6 p/Share	829 Reduced 1.93%	42,123 Common Stock
Nov 10 2025	SELL Open market or private sale	$136,960 $68.48 p/Share	2,000 Reduced 4.45%	42,952 Common Stock
Oct 01 2025	SELL Open market or private sale	$150,780 $75.39 p/Share	2,000 Reduced 4.26%	44,952 Common Stock
Sep 02 2025	SELL Open market or private sale	$292,600 $73.15 p/Share	4,000 Reduced 7.85%	46,952 Common Stock
May 01 2025	BUY Grant, award, or other acquisition	-	4,165 Added 7.56%	50,952 Common Stock
Apr 25 2024	BUY Grant, award, or other acquisition	-	6,501 Added 12.2%	46,787 Common Stock

May 05 2023	BUY Grant, award, or other acquisition	-	8,065 Added 16.68%	40,286 Common Stock
Nov 16 2022	SELL Bona fide gift	-	5,998 Reduced 15.69%	32,221 Common Stock
May 05 2022	BUY Grant, award, or other acquisition	-	6,206 Added 13.97%	38,219 Restricted Stock Units
May 05 2021	BUY Grant, award, or other acquisition	-	5,230 Added 14.04%	32,013 Restricted Stock Units

Also insider at

SYNH

Syneos Health, Inc. Healthcare

Director

EDIT

Editas Medicine, Inc. Healthcare

Director